Published in Crit Rev Oncol Hematol on March 20, 2010
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer (2011) 1.34
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol (2013) 1.17
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2012) 1.03
Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. Cancer Res (2013) 1.00
Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res (2012) 0.99
IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget (2014) 0.98
Api6/AIM/Spα/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinoma. Cancer Res (2011) 0.98
Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol (2013) 0.95
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95
Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells. PLoS One (2013) 0.91
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91
Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol (2013) 0.91
Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res (2014) 0.90
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron (2015) 0.89
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88
In vivo immune cell distribution of gold nanoparticles in naïve and tumor bearing mice. Small (2013) 0.87
Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. J Leukoc Biol (2013) 0.86
Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. J Transl Med (2015) 0.83
Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83
Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development. PLoS One (2013) 0.83
Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol Clin Oncol (2013) 0.83
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology (2014) 0.82
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immunother (2014) 0.82
New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol (2012) 0.80
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol (2011) 0.79
Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. J Leukoc Biol (2014) 0.78
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. Vaccines (Basel) (2016) 0.75
Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther (2016) 0.75
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. Front Immunol (2016) 0.75
Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron (2014) 0.75
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget (2016) 0.75
Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. Oncoimmunology (2016) 0.75
Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther (2013) 0.75
Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). Oncoimmunology (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
Cancer immunology. N Engl J Med (2008) 5.22
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell (2008) 3.56
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 2.28
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A (2004) 1.75
Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol (2006) 1.74
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol (2008) 1.63
Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol (2008) 1.49
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol (2008) 1.44
Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother (2003) 1.41
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res (2007) 1.35
Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood (2008) 1.34
Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia (2008) 1.30
Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood (2004) 1.30
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer (2009) 1.25
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16
Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood (2006) 1.08
Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst (2000) 1.07
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol (2007) 1.02
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood (2004) 1.00
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther (2009) 1.00
Imatinib mesylate--uncovering a fast track to adaptive immunity. N Engl J Med (2006) 0.95
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica (2008) 0.87
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother (2008) 0.87
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Self-assembling protein microarrays. Science (2004) 3.37
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
The increasing incidence of thyroid cancer: the influence of access to care. Thyroid (2013) 3.00
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol (2008) 2.05
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res (2004) 1.85
Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature (2012) 1.75
Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75
Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity (2011) 1.72
Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol (2010) 1.70
Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest (2013) 1.57
Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55
Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg (2007) 1.48
The basis of racial differences in the incidence of thyroid cancer. Ann Surg Oncol (2008) 1.43
Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 1.38
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35
Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol (2011) 1.29
Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid (2010) 1.25
Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope (2011) 1.24
Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer Causes Control (2011) 1.20
NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer (2004) 1.17
OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther (2002) 1.13
HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett (2009) 1.13
Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol (2013) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Discrimination of benign and neoplastic mucosa with a high-resolution microendoscope (HRME) in head and neck cancer. Ann Surg Oncol (2012) 1.11
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol (2012) 1.05
Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 1.04
Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer (2013) 1.04
T cell–derived inducible nitric oxide synthase switches off Th17 cell differentiation. J Exp Med (2013) 1.03
Rates of malignancy in incidentally discovered thyroid nodules evaluated with sonography and fine-needle aspiration. J Ultrasound Med (2005) 1.02
Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res (2012) 1.00
Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res (2013) 0.97
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95
Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol (2004) 0.93
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91
Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol (2010) 0.91
Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr (2014) 0.90
Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res (2014) 0.90
High-Resolution Optical Imaging of Benign and Malignant Mucosa in the Upper Aerodigestive Tract: An Atlas for Image-Guided Surgery. ISRN Minim Invasive Surg (2012) 0.87
In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother (2003) 0.85
IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther (2003) 0.84
γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers. PLoS One (2012) 0.83
Optical imaging with a high-resolution microendoscope to identify cholesteatoma of the middle ear. Laryngoscope (2013) 0.83
R-Ras is required for murine dendritic cell maturation and CD4+ T-cell priming. Blood (2011) 0.83
A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother (2011) 0.82
Advancements in immune tolerance. Adv Drug Deliv Rev (2007) 0.82
Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer. Cancer Sci (2014) 0.82
Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. J Cell Sci Ther (2011) 0.79
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep (2012) 0.78
Reduced impact of nodal metastases as a prognostic factor for tonsil cancer in the HPV era. Eur Arch Otorhinolaryngol (2013) 0.78
Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer. Curr Oncol Rep (2014) 0.78
Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology (2013) 0.78
Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver. Hum Gene Ther (2002) 0.77
Protein marker profiling in different T classification in laryngeal squamous cell carcinoma. Head Neck (2014) 0.77
Tamoxifen therapy for aggressive fibromatosis of the posterior triangle of the neck. Otolaryngol Head Neck Surg (2007) 0.76
Diabetes attenuates urothelial modulation of detrusor contractility and spontaneous activity. Int J Urol (2014) 0.76
Geographic differences in academic promotion practices, fellowship training, and scholarly impact. Am J Otolaryngol (2013) 0.76
Assessment of the Addition of Hypoalbuminemia to ACS-NSQIP Surgical Risk Calculator in Colorectal Cancer. Medicine (Baltimore) (2016) 0.75
A dual-boron-cored luminogen capable of sensing and imaging. Chem Commun (Camb) (2015) 0.75
Abridged Abstracts From the Medical Literature. Dis Colon Rectum (2022) 0.75
Emergency parotidectomy for penetrating zone III neck trauma. Arch Surg (2007) 0.75
Transoral robotic surgery for the management of oropharyngeal minor salivary gland tumors. Head Neck (2013) 0.75
Relaxation of a field-unwound cholesteric liquid crystal. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 0.75
Crucial effects of the anisotropy on optical field induced pattern formation in nematic liquid crystal films. Opt Express (2004) 0.75
Prevalence of severe obstructive sleep apnea in pediatric adenotonsillectomy patients. Laryngoscope (2014) 0.75
Treatment strategies in low-volume metastatic castration-resistant prostate cancer. Curr Opin Urol (2017) 0.75
Thyroglossal duct cyst carcinoma: case report and review of the literature. Ear Nose Throat J (2013) 0.75
Mycosis fungoides: a case of tonsil involvement. Arch Otolaryngol Head Neck Surg (2006) 0.75